Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2018


      The expansive scope of general internal medicine makes it difficult to identify practice-changing medical literature. Clinical updates can be facilitated by synthesizing relevant articles and implications for practice. Six internal medicine physicians reviewed the titles and abstracts in the 7 general internal medicine clinical outpatient journals with the highest impact factor and relevance to the internal medicine outpatient physician: New England Journal of Medicine (NEJM), Lancet, Annals of Internal Medicine, Journal of the American Medical Association (JAMA), JAMA-Internal Medicine, British Medical Journal (BMJ), and Public Library of Science (PLoS) Medicine. The following collections of article synopses and databases were also reviewed: American College of Physicians Journal Club, NEJM Journal Watch, BMJ Evidence-Based medicine, McMaster/DynaMed Evidence Alerts, and Cochrane Reviews. A modified Delphi method was used to gain consensus on articles based on clinical relevance to outpatient Internal Medicine, potential impact on practice, and strength of evidence. Article qualities and importance were debated until consensus was reached. Clusters of articles pertinent to the same topic were considered together. In total, 7 practice-changing articles were included.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • US Preventive Services Task Force
        • Curry S.J.
        • Krist A.H.
        • et al.
        Screening for cervical cancer: US Preventive Services Task Force recommendation statement.
        JAMA. 2018; 320: 674-686
        • Moyer V.A.
        • Preventive Services Task Force U.S.
        Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2012; 156 (W312): 880-891
        • Melnikow J.
        • Henderson J.T.
        • Burda B.U.
        • Senger C.A.
        • Durbin S.
        • Weyrich M.S.
        Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force.
        JAMA. 2018; 320: 687-705
        • Melnikow J.
        • Henderson J.T.
        • Burda B.U.
        • Senger C.A.
        • Durbin S.
        • Soulsby M.A.
        Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the US Preventive Services Task Force.
        Agency for Healthcare Research and Quality, Rockville, MD2018
        • Kim J.J.
        • Burger E.A.
        • Regan C.
        • Sy S.
        Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force.
        JAMA. 2018; 320: 706-714
        • Kim J.J.
        • Burger E.A.
        • Regan C.
        • Sy S.
        Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
        Agency for Healthcare Research and Quality, Rockville, MD2018
        • Reid I.R.
        • Horne A.M.
        • Mihov B.
        • et al.
        Fracture prevention with zoledronate in older women with osteopenia.
        N Engl J Med. 2018; 379: 2407-2416
        • Murad M.H.
        • Drake M.T.
        • Mullan R.J.
        • et al.
        Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis.
        J Clin Endocrinol Metab. 2012; 97: 1871-1880
        • Siris E.S.
        • Chen Y.T.
        • Abbott T.A.
        • et al.
        Bone mineral density thresholds for pharmacological intervention to prevent fractures.
        Arch Intern Med. 2004; 164: 1108-1112
        • Zheng S.L.
        • Roddick A.J.
        • Aghar-Jaffar R.
        • et al.
        Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis.
        JAMA. 2018; 319: 1580-1591
        • Wanner C.
        • Lachin J.M.
        • Inzucchi S.E.
        • et al.
        Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.
        Circulation. 2018; 137: 119-129
        • Patorno E.
        • Goldfine A.B.
        • Schneeweiss S.
        • et al.
        Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
        BMJ. 2018; 360: k119
        • McManus R.J.
        • Mant J.
        • Franssen M.
        • et al.
        Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial.
        Lancet. 2018; 391: 949-959
        • Whelton P.K.
        • Carey R.M.
        • Aronow W.S.
        • et al.
        2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2018; 138: e484-e594
        • Mills K.T.
        • Obst K.M.
        • Shen W.
        • et al.
        Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: a systematic review and meta-analysis.
        Ann Intern Med. 2018; 168: 110-120
        • Banegas J.R.
        • Ruilope L.M.
        • de la Sierra A.
        • et al.
        Relationship between clinic and ambulatory blood-pressure measurements and mortality.
        N Engl J Med. 2018; 378: 1509-1520
        • Niihara Y.
        • Miller S.T.
        • Kanter J.
        • et al.
        A phase 3 trial of L-glutamine in sickle cell disease.
        N Engl J Med. 2018; 379: 226-235
        • Niihara Y.
        • Zerez C.R.
        • Akiyama D.S.
        • Tanaka K.R.
        Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential.
        Am J Hematol. 1998; 58: 117-121
        • Raskob G.E.
        • van Es N.
        • Verhamme P.
        • et al.
        Edoxaban for the treatment of cancer-associated venous thromboembolism.
        N Engl J Med. 2018; 378: 615-624
        • Lee A.Y.
        • Levine M.N.
        • Baker R.I.
        • et al.
        Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
        N Engl J Med. 2003; 349: 146-153
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352
        • Lyman G.H.
        • Bohlke K.
        • Falanga A.
        American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
        J Oncol Pract. 2015; 11: e442-e444
        • Farge D.
        • Debourdeau P.
        • Beckers M.
        • et al.
        International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
        J Thromb Haemost. 2013; 11: 56-70
        • Mitchell C.M.
        • Reed S.D.
        • Diem S.
        • et al.
        Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial.
        JAMA Intern Med. 2018; 178: 681-690
        • Barenberg B.J.
        • Smith T.
        • Nihira M.A.
        Compounded estradiol cream: a cost conscious alternative.
        J Okla State Med Assoc. 2014; 107: 155-156
        • GoodRx
        Website home page.
        (Available at)
        Date accessed: January 17, 2019
        • Wysocki S.
        • Kingsberg S.
        • Krychman M.
        Management of vaginal atrophy: implications from the REVIVE survey.
        Clin Med Insights Reprod Health. 2014; 8: 23-30
        • Bachmann G.
        • Lobo R.A.
        • Gut R.
        • Nachtigall L.
        • Notelovitz M.
        Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
        Obstet Gynecol. 2008; 111: 67-76
        • Simunic V.
        • Banovic I.
        • Ciglar S.
        • Jeren L.
        • Pavicic Baldani D.
        • Sprem M.
        Local estrogen treatment in patients with urogenital symptoms.
        Int J Gynaecol Obstet. 2003; 82: 187-197
        • Cardozo L.
        • Bachmann G.
        • McClish D.
        • Fonda D.
        • Birgerson L.
        Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.
        Obstet Gynecol. 1998; 92: 722-727
        • Eriksen P.S.
        • Rasmussen H.
        Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study.
        Eur J Obstet Gynecol Reprod Biol. 1992; 44: 137-144